1. ALLA AKTIER
  2. NYHETER
  3. ZICCUM

Ziccum

Nyheter Ziccum Nyheter alla bolag

Ziccum signs Evaluation agreement with ReCode Therapeutics for LaminarPace mRNA study

Ziccum AB (publ) has signed an Evaluation Agreement with ReCode Therapeutics, Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, for evaluation of LaminarPace enabling dry powder forms of ReCode’s proprietary therapeutic modalities.

Ziccum AB signed an Evaluation agreement with ReCode on June 19th, 2024. The study will focus on evaluating Ziccum’s formulation and drying technology LaminarPace to enable dry powder forms of ReCode material: therapeutic messenger-RNA in specific liquid lipid nanoparticle formulation, mRNA/LNP, on ReCode’s proprietary SORT platform.

The LaminarPace performance will be evaluated by analytical assessment of the resulting mRNA/LNP dry product, with technical parameters as well as mRNA activity in cell transfection.

CEO Ann Gidner: “We are delighted to take our dialogue with ReCode forward to a formal collaboration. The potential of enabling new and optimal applications of the targeting mRNA technology of ReCode, and their position as a leader in the intensely growing mRNA field, is indeed enticing. We are most happy to add such a strong partner and look forward to getting this work started.”

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Jonas Ekblom,
Chairman of the Board, Ziccum AB
Mail: ekblom@ziccum.com
 
Ziccum’s Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on https://eucaps.com/ziccum

About Ziccum

Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Ziccum signs Evaluation agreement with ReCode Therapeutics for LaminarPace mRNA study

Datum 2024-06-19, kl 10:00
Källa MFN
Bifogade filer
Ziccum signs Evaluation agreement with ReCode Therapeutics for LaminarPace mRNA study
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!